From scarcity biology to cash trials: how unconditional income moved epigenetic aging in children

What scarcity biology had already established before the cash trial

Before this trial, the case for a poverty-aging link rested on observational cohorts. In the Texas Twin Project, children and adolescents from more disadvantaged families and neighborhoods showed faster salivary DunedinPoAm pace of aging (r = 0.18 for both family and neighborhood disadvantage), and this gradient survived adjustment for BMI and pubertal development [8]. A longitudinal cohort of 359 adults found that low childhood socioeconomic status predicted faster DunedinPACE at age 50 (β = 0.05, 95% CI 0.02–0.08), with adulthood SES partially mediating the association [2]. A separate MIDUS analysis reported that greater life-course socioeconomic disadvantage was associated with higher DunedinPACE (b = 0.27) and that DunedinPACE mediated links between disadvantage and slower gait, chair-stand time, and lower survival [9]. Meta-analytic work added an important qualifier: across 46 studies, threat-related adversity was associated with accelerated cellular aging (d = −0.43), whereas deprivation and low SES were not [7]. That specificity made the DunedinPACE signal in low-SES children theoretically contested, not settled.

These studies established that DunedinPACE-type measures correlate with social disadvantage and predict functional outcomes, but they could not distinguish causation from confounding by genetics, selection, or unmeasured environments. The Baby's First Years trial was designed to fill exactly that gap by randomizing income itself [1].

The randomized cash design and the 0.17 SD DunedinPACE result

Baby's First Years enrolled 1,000 mother–child dyads across four US sites and randomized mothers to $333/month (high cash, n = 400) or $20/month (low cash, n = 600) beginning at the child's birth, with payments later extended through 76 months [1]. The high-cash arm raised family income by roughly $4,000 per year, about 18% [1]. DunedinPACE and Epigenetic-g were preregistered secondary outcomes; salivary DNA methylation was analyzed at age 4 in 735 children and 777 mothers [1]. The high-cash group showed a −0.17 SD difference in children's DunedinPACE (95% CI −0.32 to −0.01, P = 0.037) [1]. Because DunedinPACE values above 1 indicate faster biological aging per chronological year, a negative difference means slower epigenetic aging in the high-cash arm [1].

The effect size is modest but not trivial for a pure income transfer. For comparison, a 25% calorie restriction trial in adults produced a DunedinPACE difference of d = −0.29 (95% CI −0.45 to −0.13) at 12 months [1]. The cash trial's −0.17 SD is smaller, but it was achieved in 4-year-olds through an intervention that changed no health behavior directly. The trial authors note that if accelerated aging accrues cumulative biological costs, even modest early deceleration could yield outsized public health returns—but only if the effect persists [1].

Why the cognitive biomarker and maternal results did not follow

The trial's second preregistered hypothesis—that high cash would increase children's Epigenetic-g, a methylation profile resembling adults with higher general cognitive function—was not supported [1]. The standardized effect was similar in magnitude to the DunedinPACE result but significance varied across sensitivity checks, and the authors describe the evidence as inconsistent [1]. This dissociation matters because Epigenetic-g was modeled on adult cognitive performance in Generation Scotland [1], and the trial found no concurrent treatment effects on children's executive function, receptive vocabulary, BMI, or maternal-reported health [1]. The authors interpret the pattern as consistent with epigenetic canalization: early economic conditions may shape the epigenome without producing detectable behavioral differences at age 4 [1].

Mothers showed no epigenetic response to cash on either DunedinPACE or Epigenetic-g [1]. In mothers, faster DunedinPACE was associated with higher BMI and lower executive function, but the intervention did not move the biomarker [1]. This null is important for interpretation: the child finding is not a generic stress-reduction signal affecting all family members. It is specific to the developing child's epigenome during the first four years.

How the epigenetic result sits against cash transfer meta-analytic evidence

A systematic review and meta-analysis of cash transfer trials in low- and middle-income countries concluded that cash alone produces null or small effects on child cognitive, language, and socio-emotional development, and that conditional or cash-plus designs are needed for developmental gains [4]. That literature would predict little cognitive benefit from an unconditional transfer, which aligns with the trial's null Epigenetic-g result [1][4]. The DunedinPACE finding does not contradict the meta-analysis; it identifies a different endpoint—biological aging rather than tested cognition—where unconditional cash may register before behavioral change appears [1].

The comparison also exposes a design difference. The meta-analysis covered children ages 0–8 in LMIC settings with varying transfer sizes and conditionality [4]. Baby's First Years is a US trial with a large, sustained unconditional transfer beginning at birth [1]. Whether the DunedinPACE effect would replicate in LMIC cash programs, or whether conditional designs would produce larger epigenetic effects, is untested.

What the trial cannot yet tell us about durability and health

Several boundaries limit the conclusion. The epigenetic outcomes were measured only at age 4, so persistence is unknown; the trial authors state explicitly that whether the effect endures and how it relates to behavioral and health outcomes remains unknown [1]. The sample is US mothers with low income and their children, with saliva-based methylation, and the trial was powered for developmental outcomes rather than epigenetic secondary outcomes [1]. DunedinPACE was developed and validated primarily in adult blood cohorts, and age norms for the measure are still being established; a 2026 analysis of 37,855 adults documented that DunedinPACE rises linearly with age and differs by sex, and noted that clinical interpretation in children remains unclear [3]. Applying adult-derived pace-of-aging metrics to 4-year-olds is therefore an extrapolation.

Intervention studies in other populations show that DunedinPACE can move but not always in expected directions. In a 12-week ketogenic diet trial in adults with drug-resistant epilepsy, mean group-level DunedinPACE change was small and non-significant, though individual trajectories varied and trajectory pattern correlated with quality-of-life improvement [6]. That study underscores that DunedinPACE is dynamic and context-sensitive, which cuts both ways for the cash trial: it supports modifiability, but also warns that a single 4-year measurement may not capture a stable biological trajectory. Finally, DNA methylation biomarkers of cognitive development are being validated in other exposure contexts, such as lead-related FAM50B/PTCHD3 methylation predicting infant neurodevelopment [5], but these are different loci and different exposures, so they do not directly validate or undermine Epigenetic-g. The honest summary is that the trial produced one robust positive signal, one null, and a set of open questions about durability, tissue specificity, and downstream health relevance that only longer follow-up can answer.

About These Sources

This research page is built on 9 peer-reviewed studies — published from 2019 to 2026, 7 from 2024 or later, collectively cited 362 times — selected as the most relevant from 11 studies that passed quality screening, drawn from 88 papers retrieved from a database of over 500 million.

Sources used in this answer